Anlotinib Hydrochloride in Intra-Abdominal Desmoplastic Small Round Cell Tumor: Case Evidence and Mechanistic Insights

Study Background and Research Question

Intra-abdominal desmoplastic small round cell tumor (IADSRCT) is a rare, highly aggressive malignancy that predominantly affects children and young adults. Characterized by the pathognomonic EWS-WT1 gene fusion, IADSRCT presents with poor prognosis and a 5-year survival rate of only 15%–30%. Current management relies on surgery, chemotherapy, and radiotherapy, yet no standardized or targeted therapies are established for this sarcoma subtype (paper). Against this backdrop, the referenced study sought to address whether anlotinib hydrochloride—a novel multi-target tyrosine kinase inhibitor (TKI) with anti-angiogenic properties—could offer clinical benefit in metastatic IADSRCT.

Key Innovation from the Reference Study

This report, published by Chen and Feng, is the first to document successful treatment of metastatic IADSRCT with anlotinib. The innovation stems from repositioning a multi-target TKI—previously validated in more common malignancies such as non-small-cell lung cancer and renal cell carcinoma—for a rare sarcoma with limited options. Anlotinib’s inhibition of receptor tyrosine kinases involved in angiogenesis (VEGFR1–3, FGFR1–4, PDGFRα/β, c-Kit, Met) provided a rationale for targeting the tumor’s vascular supply and growth pathways (paper).

Methods and Experimental Design Insights

The study centers on a 38-year-old male with confirmed IADSRCT, initially managed with surgical resection and six cycles of adjuvant chemotherapy. Disease progression was documented by CT scan, revealing lymph node metastases. Anlotinib was initiated as a salvage and maintenance therapy. The clinical course, radiological response, and adverse events were prospectively recorded. The case is contextualized with a literature review summarizing the mechanistic rationale for anti-angiogenic intervention in IADSRCT (paper).

Protocol Parameters

• assay | CT-based tumor response | Not numerically quantified; radiological shrinkage observed after four cycles | Real-world response assessment in rare tumor context | paper
• assay | VEGFR/FGFR/PDGFR pathway inhibition | Not directly measured in this case | Mechanistic rationale from preclinical literature | workflow_recommendation
• assay | Adverse event monitoring | High triglycerides, fatigue (graded, manageable) | Safety profile in real-world setting | paper
• assay | Capillary tube formation assay | IC₅₀ values: VEGFR2 (5.6 ± 1.2 nM), PDGFRβ (8.7 ± 3.4 nM), FGFR1 (11.7 ± 4.1 nM) | Quantitative anti-angiogenic activity in vitro | product_spec

Core Findings and Why They Matter

After four cycles of anlotinib, significant reduction in metastatic lymph nodes was observed radiographically. The patient tolerated therapy with manageable toxicity, consisting mainly of hypertriglyceridemia and fatigue. Maintenance therapy was continued, and the patient’s general condition remained stable. This case demonstrates that multi-target tyrosine kinase inhibition, particularly of angiogenic pathways, can induce clinical response even in aggressive, treatment-refractory sarcomas (paper).

Mechanistically, anlotinib’s anti-angiogenic properties—driven by potent inhibition of VEGFR2, PDGFRβ, and FGFR1—likely underlie the tumor response. These targets are central to endothelial cell migration inhibition and capillary tube formation, both crucial for tumor vascularization and progression (internal_article, internal_article). The clinical observation reinforces preclinical expectations established in endothelial cell and in vivo models, where anlotinib has demonstrated robust ERK signaling pathway inhibition and superior activity compared to other TKIs (internal_article).

Comparison with Existing Internal Articles

Recent reviews and preclinical studies provide a mechanistic and quantitative framework for interpreting the case report. For example, "Anlotinib Hydrochloride: Potent Multi-Target Tyrosine Kin..." details the compound’s specificity for key angiogenic receptors and its superior inhibition of endothelial cell functions relevant to tumor angiogenesis (internal_article). Similarly, "Preclinical Characterization of Anlotinib: Potent VEGFR2 Inhibition" emphasizes foundational evidence for ERK pathway blockade and functional outcomes in cancer research (internal_article). The clinical case extends these findings into a new domain—rare sarcomas—bridging laboratory and bedside evidence.

Limitations and Transferability

As a single case report, the study’s findings are hypothesis-generating rather than definitive. The absence of molecular or pharmacodynamic biomarkers in the presented case limits mechanistic interpretation at the patient level. Moreover, IADSRCT’s rarity and clinical heterogeneity constrain generalizability. Prospective, multi-patient studies are needed to define the reproducibility and optimal integration of anlotinib in sarcoma protocols (paper).

Nevertheless, the case aligns with broader evidence for anti-angiogenic small molecules in cancer research, supporting further exploration of multi-target TKIs in rare and refractory neoplasms (internal_article).

Why this cross-domain matters, maturity, and limitations

Translating anti-angiogenic strategies validated in common solid tumors to rare sarcomas like IADSRCT opens new therapeutic possibilities, particularly for patients with few alternatives. However, cross-domain transfer should be guided by mechanistic plausibility and real-world safety data, as reflected in this report. The maturity of evidence remains early-phase, underscoring the need for further research.

Research Support Resources

For investigators designing translational or preclinical studies on angiogenesis inhibition, Anlotinib hydrochloride (SKU C8688) offers a well-characterized research tool, with validated potency against VEGFR2, PDGFRβ, and FGFR1 and suitability for functional assays and cell-based models (source: product_spec). APExBIO supplies this compound for research use, supporting workflows in endothelial cell migration inhibition, capillary tube formation assay, and ERK pathway studies. Researchers should consult product documentation and relevant literature to optimize experimental design.